- Home
- INLF vs NXTC Comparison
INLF vs NXTC Comparison
Compare INLF & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INLF
- NXTC
- Stock Information
- Founded
- INLF 2016
- NXTC 2015
- Country
- INLF China
- NXTC United States
- Employees
- INLF N/A
- NXTC N/A
- Industry
- INLF Industrial Machinery/Components
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- INLF Industrials
- NXTC Health Care
- Exchange
- INLF Nasdaq
- NXTC Nasdaq
- Market Cap
- INLF 16.2M
- NXTC 13.9M
- IPO Year
- INLF 2025
- NXTC 2019
- Fundamental
- Price
- INLF $1.07
- NXTC $0.40
- Analyst Decision
- INLF
- NXTC Strong Buy
- Analyst Count
- INLF 0
- NXTC 2
- Target Price
- INLF N/A
- NXTC $3.50
- AVG Volume (30 Days)
- INLF 3.6M
- NXTC 341.5K
- Earning Date
- INLF 01-01-0001
- NXTC 07-31-2025
- Dividend Yield
- INLF N/A
- NXTC N/A
- EPS Growth
- INLF 18.78
- NXTC N/A
- EPS
- INLF 0.13
- NXTC N/A
- Revenue
- INLF $15,796,983.00
- NXTC N/A
- Revenue This Year
- INLF N/A
- NXTC N/A
- Revenue Next Year
- INLF N/A
- NXTC N/A
- P/E Ratio
- INLF $8.25
- NXTC N/A
- Revenue Growth
- INLF 25.27
- NXTC N/A
- 52 Week Low
- INLF $0.77
- NXTC $0.22
- 52 Week High
- INLF $21.00
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- INLF N/A
- NXTC 37.68
- Support Level
- INLF N/A
- NXTC $0.42
- Resistance Level
- INLF N/A
- NXTC $0.50
- Average True Range (ATR)
- INLF 0.00
- NXTC 0.04
- MACD
- INLF 0.00
- NXTC -0.01
- Stochastic Oscillator
- INLF 0.00
- NXTC 4.17
About INLF INLIF LIMITED Ordinary Shares
INLIF Ltd, through its subsidiary, is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms. In addition, it offers installation and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The company portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.